Literature DB >> 7059424

Bioavailability of sublingual ergotamine.

P Tfelt-Hansen, L Paalzow, J J Ibraheem.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059424      PMCID: PMC1401977          DOI: 10.1111/j.1365-2125.1982.tb01366.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  CLINICAL TRIAL OF INHALED ERGOTAMINE TARTRATE IN MIGRAINE.

Authors:  J CROOKS; S A STEPHEN; W BRASS
Journal:  Br Med J       Date:  1964-01-25

2.  Buccal absorption of ergotamine.

Authors:  J M Sutherland; W D Hooper; M J Eadie; J H Tyrer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-10       Impact factor: 10.154

3.  Plethysmographic comparison of sublingual and intramuscular ergotamine.

Authors:  T Winsor
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

4.  A new technique for recording compliance of human hand veins.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

5.  The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve.

Authors:  P Tfelt-Hansen; J H Eickhoff; J Olesen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-08
  5 in total
  2 in total

Review 1.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

2.  Ergotamine abuse and extra-hepatic portal hypertension.

Authors:  P E Fisher; D B Silk; N Menzies-Gow; M Dingle
Journal:  Postgrad Med J       Date:  1985-05       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.